Charles River, Genentech Extend Discovery Alliance
News Oct 13, 2016
Charles River Laboratories International Inc has announced that it has extended its longstanding integrated drug discovery alliance with Genentech. “We are proud to work with Genentech to identify early-stage molecules that will ultimately result in innovative treatments for patients,” said John Montana, Executive Director, Integrated Drug Discovery at Charles River.
“Our long-term collaboration with Genentech has been mutually beneficial for both companies. As our teams have demonstrated, when biotechs and CROs work together, they have the ability to enhance innovations in early discovery research.”
Through this alliance, Charles River provides Genentech early discovery services, including medicinal chemistry, in vitro and in vivo biology, structural biology, and computer-aided drug design, to help identify promising candidates for preclinical development. Charles River and Genentech have engaged in an ongoing program since 2005, with the latest extension providing a three-year continuation.
The program began with a single project involving medicinal chemistry, and has evolved over the past 11 years to a multi-disciplinary collaboration drawing on Charles River’s leading researchers in chemistry, biology and pharmacology.
MIT researchers have developed a cryptographic system that could help neural networks identify promising drug candidates in massive pharmacological datasets, while keeping the data private. Secure computation done at such a massive scale could enable broad pooling of sensitive pharmacological data for predictive drug discovery.
Biochemists, microbiologists, drug discovery experts and infectious disease doctors have teamed up in a new study that shows antibiotics are not always necessary to cure sepsis in mice. Instead of killing causative bacteria with antibiotics, researchers treated infected mice with molecules that block toxin formation in bacteria.READ MORE